Table 1 Current status of clinical trials of biologics specifically targeting the Wnt/β-catenin pathway (ligands or receptors)

OTSA101 (Centre Léon Bérard, OncoTherapy Science)

FZD₁₀

mAb

Synovial sarcoma. Antibody-radionuclide conjugate (⁹⁰Y)

I

OMP-54F28 (Oncomed Pharma)

Wnt

Fzd8-Fc (scavenging receptor)

HCC, liver cancer, ovarian cancer, pancreatic cancer, other solid tumors

I

Vantictumab (Oncomed Pharma)

FZD₁, ₂, ₅, ₇, ₈

mAb

Solid tumors (completed), NSCLC, metastatic breast cancer, pancreatic cancer, (active, as a combination with chemiotherapy)

I

Foxy-5 (WntResearch AB)

FZD₅

Peptide

Metastatic breast cancer, colorectal cancer, prostate cancer

I